August 2025 marks two full years that I’ve enjoyed the benefits from my trial of epcoritamab, a bispecific T-cell-engaging monoclonal antibody for my CLL. But the last remains of my chronic lymphocytic leukemia (CLL) have remained stubbornly persistent for about a year and a half.